https://inventivapharma.com/fr/leurope-rend-un-avis-favorable-pour-la-designation-de-liva337-comme-medicament-orphelin-dans-le-traitement-de-la-sclerodermie-systemique-ssc/ 2014-11-03T00:00:00+00:00 https://inventivapharma.com/inventiva-receives-another-positive-opinion-on-orphan-drug-designation-in-the-european-union-for-iva337-for-idiopathic-pulmonary-fibrosis/ 2014-12-02T00:00:00+00:00 https://inventivapharma.com/fr/leurope-rend-un-nouvel-avis-positif-pour-la-designation-de-liva337-comme-medicament-orphelin-dans-le-traitement-de-la-fibrose-pulmonaire-idiopathique/ 2014-12-02T00:00:00+00:00 https://inventivapharma.com/sensiq-technologies-and-inventiva-set-up-a-european-center-of-excellence-in-surface-plasmon-resonance-spr-technologies/ 2015-02-09T00:00:00+00:00 https://inventivapharma.com/fr/sensiq-technologies-et-inventiva-ouvrent-un-centre-europeen-dexcellence-en-spr-surface-plasmon-resonance/ 2015-02-09T00:00:00+00:00 https://inventivapharma.com/european-eurostars-funding-received-for-epigenetics-program-nsd2/ 2015-12-03T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-recoit-une-subvention-du-programme-europeen-eurostars-pour-son-programme-epigenetique-nsd2/ 2015-12-03T00:00:00+00:00 https://inventivapharma.com/iva337-delivers-significant-therapeutic-advances-in-fibrosis-a-major-public-health-challenge/ 2016-01-28T00:00:00+00:00 https://inventivapharma.com/fr/avancee-therapeutique-significative-pour-iva337-dans-les-fibroses-un-enjeu-majeur-de-sante-publique/ 2016-01-28T00:00:00+00:00 https://inventivapharma.com/inventiva-rewarded-for-its-innovative-approach-with-iva337-at-the-4th-systemic-sclerosis-world-congress/ 2016-02-25T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-recompensee-pour-son-approche-innovante-avec-liva337-lors-du-4eme-congres-mondial-sur-la-sclerodermie-systemique/ 2016-02-25T00:00:00+00:00 https://inventivapharma.com/boehringer-ingelheim-and-inventiva-collaborate-to-develop-potential-new-treatments-for-idiopathic-pulmonary-fibrosis/ 2016-05-31T00:00:00+00:00 https://inventivapharma.com/fr/boehringer-ingelheim-et-inventiva-signent-un-partenariat-pour-developper-de-nouveaux-traitements-exploratoires-contre-la-fibrose-pulmonaire-idiopathique-2/ 2016-05-31T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-receipt-of-e2-3-million-in-grant-funding-for-yap-tead-protein-research-program/ 2016-09-19T00:00:00+00:00 https://inventivapharma.com/fr/obtention-dun-financement-de-23-millions-deuros-pour-le-programme-de-recherche-sur-les-proteines-yap-tead/ 2016-09-19T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-initiation-of-phase-iib-clinical-trial-of-iva337-for-treatment-of-non-alcoholic-steatohepatitis-nash/ 2017-01-03T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-lancement-de-letude-de-phase-iib-diva337-dans-le-traitement-de-la-nash-steatose-hepatique-non-alcoolique/ 2017-01-03T00:00:00+00:00 https://inventivapharma.com/inventiva-hits-clinical-milestone-with-enrollment-of-100th-patient-in-iva337-phase-2b-fasst-trial-in-systemic-sclerosis-ssc/ 2017-04-10T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-franchit-une-etape-clinique-cle-avec-le-recrutement-du-100eme-patient-dans-letude-de-phase-2b-fasst-evaluant-iva337-dans-la-sclerodermie-systemique-ssc/ 2017-04-10T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-presentation-of-preclinical-results-on-iva337-in-nash-at-the-international-liver-congress-2017-easl/ 2017-04-20T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presente-de-nouveaux-resultats-pre-cliniques-avec-iva337-dans-la-nash-lors-de-linternational-liver-congress-easl/ 2017-04-20T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-positive-results-of-12-month-primate-toxicity-study-with-iva337/ 2017-05-15T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-les-resultats-positifs-de-letude-de-toxicite-de-12-mois-chez-le-primate-avec-iva337/ 2017-05-15T00:00:00+00:00 https://inventivapharma.com/dr-nanna-luneborg-principal-of-novo-ventures-joins-inventivas-board/ 2017-05-30T00:00:00+00:00 https://inventivapharma.com/fr/dr-nanna-luneborg-directeur-de-participations-chez-novo-ventures-rejoint-le-conseil-dadministration-dinventiva/ 2017-05-30T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-at-the-jefferies-2017-global-healthcare-conference/ 2017-06-06T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presentera-a-la-conference-global-healthcare-2017-de-jefferies/ 2017-06-06T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-peer-review-publication-of-iva337-data-in-pre-clinical-nash-models/ 2017-06-20T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-publication-dans-une-revue-a-comite-de-lecture-de-donnees-sur-iva337-dans-des-modeles-precliniques-de-la-nash/ 2017-06-20T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-new-compelling-data-on-odiparcil-iva336-to-be-presented-at-mps-society-national-conference/ 2017-06-29T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presentera-de-nouvelles-donnees-convaincantes-dodiparcil-iva336-lors-de-la-conference-nationale-de-la-mps-society/ 2017-06-29T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-new-data-on-iva337-at-the-15th-international-workshop-on-scleroderma-research-in-pittsburgh-usa/ 2017-07-27T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presentera-de-nouveaux-resultats-sur-iva337-lors-du-15eme-congres-scientifique-international-workshop-on-scleroderma-research-a-pittsburgh-aux-etats-unis/ 2017-07-27T00:00:00+00:00 https://inventivapharma.com/odiparcil-awarded-orphan-drug-designation-for-the-treatment-of-mps-vi-by-the-fda/ 2017-08-10T00:00:00+00:00 https://inventivapharma.com/fr/odiparcil-recoit-la-designation-de-medicament-orphelin-par-la-fda-americaine-dans-le-traitement-de-la-mps-vi/ 2017-08-10T00:00:00+00:00 https://inventivapharma.com/inventivas-odiparcil-awarded-orphan-drug-designation-for-the-treatment-of-mps-vi-by-the-european-medicines-agency/ 2017-08-29T00:00:00+00:00 https://inventivapharma.com/fr/odiparcil-dinventiva-recoit-la-designation-de-medicament-orphelin-par-lagence-europeenne-des-medicaments-pour-le-traitement-de-la-mps-vi/ 2017-08-29T00:00:00+00:00 https://inventivapharma.com/inventiva-and-abbvie-extend-agreement-to-discover-new-potent-orally-available-small-molecule-ror%ce%b3-inverse-agonist-drug-candidates/ 2017-09-04T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-exercise-of-option-by-boehringer-ingelheim-to-jointly-develop-potential-new-treatments-for-idiopathic-pulmonary-fibrosis-ipf/ 2017-09-05T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-lexercice-par-boehringer-ingelheim-de-son-option-pour-developper-conjointement-de-nouveaux-traitements-contre-la-fibrose-pulmonaire-idiopathique-fpi/ 2017-09-05T00:00:00+00:00 https://inventivapharma.com/inventivas-iva337-given-generic-name-lanifibranor-by-the-world-health-organization-who/ 2017-09-18T00:00:00+00:00 https://inventivapharma.com/inventivas-phase-iib-fasst-trial-in-systemic-sclerosis-with-lanifibranor-completes-enrollment/ 2017-10-17T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-finalise-le-recrutement-de-son-etude-de-phase-iib-fasst-evaluant-lanifibranor-dans-la-sclerodermie-systemique/ 2017-10-17T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-at-two-upcoming-investor-conferences/ 2017-11-13T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-deux-conferences-investisseurs/ 2017-11-13T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-enrollment-of-first-patient-into-its-odiparcil-phase-iia-trial-improves-for-mps-vi/ 2018-01-03T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-linclusion-du-premier-patient-dans-son-etude-de-phase-iia-improves-menee-avec-odiparcil-dans-le-traitement-de-la-mps-vi/ 2018-01-03T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-positive-dsmb-review-in-phase-iib-fasst-trial-in-systemic-sclerosis-with-lanifibranor/ 2018-01-04T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-les-conclusions-positives-du-dsmb-de-letude-de-phase-iib-fasst-dans-la-sclerodermie-systemique-avec-le-lanifibranor/ 2018-01-04T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-in-vivo-data-with-odiparcil-at-the-14th-worldsymposium/ 2018-01-31T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presentera-des-donnees-in-vivo-sur-odiparcil-lors-du-14eme-worldsymposium/ 2018-01-31T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-positive-outcomes-of-biomarker-study-measuring-intracellular-gags-in-leukocytes-from-mps-vi-patients/ 2018-02-26T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-les-resultats-positifs-de-letude-biomarqueur-sur-les-gag-intracellulaires-dans-les-leucocytes-de-patients-atteints-de-mps-vi/ 2018-02-26T00:00:00+00:00 https://inventivapharma.com/2018-full-year-results-important-progress-in-rd-portfolio-and-solid-cash-position/ 2018-02-27T15:35:48+00:00 https://inventivapharma.com/inventiva-to-present-at-six-investor-conferences-in-march-2018/ 2018-03-08T00:00:00+00:00 https://inventivapharma.com/inventivas-paper-on-the-discovery-and-synthesis-of-its-panppar-agonist-lanifibranor-accepted-and-published-in-the-journal-of-medicinal-chemistry-of-the-american-chemical-society/ 2018-03-13T00:00:00+00:00 https://inventivapharma.com/fr/acceptation-et-publication-dun-article-dinventiva-sur-la-decouverte-et-la-synthese-de-son-agoniste-pan-ppar-lanifibranor-dans-la-revue-journal-of-medicinal-chemistry-de/ 2018-03-13T00:00:00+00:00 https://inventivapharma.com/lanifibranor-carcinogenicity-studies-progressing-as-planned-and-interim-results-in-rats-indicate-no-compound-related-urinary-bladder-tumors/ 2018-03-28T00:00:00+00:00 https://inventivapharma.com/fr/etudes-de-carcinogenicite-avec-lanifibranor-deroulement-comme-prevu-et-resultats-intermediaires-chez-le-rat-indiquent-labsence-de-cancers-de-la-vessie-lies-au-compose/ 2018-03-28T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-a-u-s-phase-ii-investigator-initiated-study-with-lanifibranor-on-non-alcoholic-fatty-liver-disease-in-patients-with-type-2-diabetes/ 2018-04-03T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-une-etude-aux-etats-unis-de-phase-ii-initiee-par-un-investigateur-avec-lanifibranor-pour-le-traitement-de-la-steatose-hepatique-non-alcoolique-chez-des-patients-atteints/ 2018-04-03T00:00:00+00:00 https://inventivapharma.com/dr-lucy-lu-is-appointed-to-the-inventiva-board-of-directors/ 2018-05-28T00:00:00+00:00 https://inventivapharma.com/wp-content/uploads/2018/05/LucyLu.jpg https://inventivapharma.com/fr/docteur-lucy-lu-est-nommee-membre-du-conseil-dadministration-dinventiva/ 2018-05-28T00:00:00+00:00 https://inventivapharma.com/wp-content/uploads/2018/05/LucyLu-1.jpg https://inventivapharma.com/inventiva-to-present-at-the-jefferies-2018-global-healthcare-conference/ 2018-05-30T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-jefferies-2018-global-healthcare-conference/ 2018-05-30T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-at-the-2018-jmp-securities-life-sciences-conference/ 2018-06-11T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-2018-jmp-securities-life-sciences-conference/ 2018-06-11T00:00:00+00:00 https://inventivapharma.com/fda-approval-of-an-investigator-initiated-ind-application-to-conduct-phase-ii-study-of-lanifibranor-in-type-2-diabetic-patients-with-non-alcoholic-fatty-liver-disease/ 2018-06-20T00:00:00+00:00 https://inventivapharma.com/fr/approbation-par-la-fda-de-la-demande-dind-a-linitiative-dun-investigateur-autorisant-letude-de-phase-ii-avec-lanifibranor-pour-le-traitement-de-la-stea/ 2018-06-20T00:00:00+00:00 https://inventivapharma.com/inventiva-2018-third-quarter-financial-update-2/ 2018-07-09T18:12:30+00:00 https://inventivapharma.com/inventiva-announces-positive-dsmb-reviews-in-both-nash-and-systemic-sclerosis-phase-iib-trials-with-lanifibranor/ 2018-07-10T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-les-conclusions-positives-des-deux-dsmb-pour-les-etudes-de-phase-iib-dans-la-sclerodermie-systemique-et-dans-la-nash-avec-le-lanifibranor/ 2018-07-10T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-poster-presentation-on-a-promising-biomarker-for-mps-vi-at-the-15th-international-symposium-on-mps-and-related-diseases/ 2018-07-26T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-une-presentation-par-affiche-concernant-un-biomarquer-prometteur-dans-la-mps-vi-lors-du-15eme-international-symposium-on-mps-and-related-diseases/ 2018-07-26T00:00:00+00:00 https://inventivapharma.com/inventiva-to-present-the-latest-findings-in-its-ror%ce%b3-program-at-the-256th-national-meeting-of-the-american-chemical-society/ 2018-08-01T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-presentera-les-derniers-resultats-de-son-programme-ror%ce%b3-lors-de-la-256eme-reunion-nationale-de-lamerican-chemical-society/ 2018-08-01T00:00:00+00:00 https://inventivapharma.com/inventivas-lanifibranor-found-to-have-good-safety-profile-following-first-assessment-of-carcinogenicity-studies-results/ 2018-08-13T00:00:00+00:00 https://inventivapharma.com/fr/une-analyse-preliminaire-des-resultats-des-etudes-de-carcinogenicite-avec-lanifibranor-dinventiva-met-en-evidence-un-bon-profil-de-securite/ 2018-08-13T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-dun-poster-sur-son-programme-dinhibiteurs-yap-tead-lors-du-symposium-de-leortc-nci-aacr-a-dublin-2/ 2018-08-22T17:47:24+00:00 https://inventivapharma.com/inventiva-to-present-at-the-h-c-wainwright-20th-annual-global-investment-conference/ 2018-08-29T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-h-c-wainwright-20th-annual-global-investment-conference/ 2018-08-29T00:00:00+00:00 https://inventivapharma.com/inventiva-advances-in-the-development-of-lanifibranor-with-the-achievement-of-three-key-milestones/ 2018-08-30T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-progresse-dans-le-developpement-du-lanifibranor-avec-le-franchissement-de-trois-nouvelles-etapes-cles/ 2018-08-30T00:00:00+00:00 https://inventivapharma.com/inventiva-launches-an-independent-working-group-to-help-increase-nash-awareness-and-establish-best-practices-for-its-treatment/ 2018-09-24T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-cree-un-groupe-de-travail-independant-pour-augmenter-la-connaissance-sur-la-nash-et-etablir-de-meilleures-pratiques-pour-son-traitement/ 2018-09-24T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-two-poster-presentations-at-the-american-college-of-rheumatology-conference/ 2018-10-10T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-de-deux-posters-lors-de-la-conference-de-l-american-college-of-rheumatology/ 2018-10-10T00:00:00+00:00 https://inventivapharma.com/inventiva-to-participate-in-the-roth-battle-of-the-nash-thrones-investor-conference/ 2018-10-12T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-roth-battle-of-the-nash-thrones-investor-conference/ 2018-10-12T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-last-visit-by-last-patient-in-its-phase-iib-ssc-trial-and-second-positive-dsmb-review-in-its-phase-iib-nash-trial-with-lanifibranor/ 2018-10-15T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-derniere-visite-du-dernier-patient-pour-son-etude-de-phase-iib-dans-la-ssc-ainsi-que-la-deuxieme-analyse-positive-du-dsmb-pour-son-etude-de-phase-iib-dans-la-nash-av/ 2018-10-15T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-two-appointments-to-its-management-team-ahead-of-future-key-development-milestones/ 2018-10-17T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-deux-nominations-au-sein-de-son-equipe-de-direction-en-prevision-detapes-cles-de-son-developpement-a-venir/ 2018-10-17T00:00:00+00:00 https://inventivapharma.com/inventiva-invited-to-present-at-stifel-2018-healthcare-conference-in-new-york-and-at-jefferies-2018-london-healthcare-conference/ 2018-10-30T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-avoir-ete-invite-pour-presenter-a-la-stifel-2018-healthcare-conference-a-new-york-et-a-la-jefferies-2018-london-healthcare-conference/ 2018-10-30T00:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-dun-poster-sur-son-programme-dinhibiteurs-yap-tead-lors-du-symposium-de-leortc-nci-aacr-a-dublin/ 2018-11-07T00:00:00+00:00 https://inventivapharma.com/inventiva-announces-poster-presentation-on-its-yap-tead-inhibitor-program-at-the-eortc-nci-aacr-symposium-in-dublin/ 2018-11-07T13:21:02+00:00 https://inventivapharma.com/fr/inventiva-invited-to-present-at-stifel-2018-healthcare-conference-in-new-york-and-at-jefferies-2018-london-healthcare-conference-2-2-2/ 2018-12-10T18:02:08+00:00 https://inventivapharma.com/inventiva-invited-to-present-at-the-37th-annual-j-p-morgan-healthcare-conference/ 2018-12-18T17:56:21+00:00 https://inventivapharma.com/fr/inventiva-invited-to-present-at-stifel-2018-healthcare-conference-in-new-york-and-at-jefferies-2018-london-healthcare-conference-2-2-2-2/ 2019-02-04T18:12:46+00:00 https://inventivapharma.com/new-results-on-lanifibranor-to-be-presented-at-the-international-liver-congress-2019/ 2019-02-04T18:15:29+00:00 https://inventivapharma.com/results-from-phase-iib-clinical-trial-with-lanifibranor-in-systemic-sclerosis/ 2019-02-18T18:58:44+00:00 https://inventivapharma.com/fr/resultats-de-letude-clinique-de-phase-iib-avec-lanifibranor-dans-la-ssc/ 2019-02-18T19:04:44+00:00 https://inventivapharma.com/fr/nouvelles-avancees-dans-le-developpement-clinique-de-lanifibranor-pour-le-traitement-de-la-nash/ 2019-02-21T17:03:17+00:00 https://inventivapharma.com/further-progress-achieved-in-the-clinical-development-of-lanifibranor-for-the-treatment-of-nash/ 2019-02-21T17:07:18+00:00 https://inventivapharma.com/fr/nouvelles-avancees-dans-le-developpement-clinique-de-lanifibranor-pour-le-traitement-de-la-nash-2/ 2019-03-05T16:55:25+00:00 https://inventivapharma.com/further-progress-achieved-in-the-clinical-development-of-lanifibranor-for-the-treatment-of-nash-2/ 2019-03-05T17:00:38+00:00 https://inventivapharma.com/fr/nouvelles-avancees-dans-le-developpement-clinique-de-lanifibranor-pour-le-traitement-de-la-nash-2-2/ 2019-03-06T16:52:56+00:00 https://inventivapharma.com/further-progress-achieved-in-the-clinical-development-of-lanifibranor-for-the-treatment-of-nash-2-2/ 2019-03-06T16:57:28+00:00 https://inventivapharma.com/further-progress-achieved-in-the-clinical-development-of-lanifibranor-for-the-treatment-of-nash-2-2-2/ 2019-04-03T16:04:38+00:00 https://inventivapharma.com/fr/nouvelles-avancees-dans-le-developpement-clinique-de-lanifibranor-pour-le-traitement-de-la-nash-2-2-2/ 2019-04-03T16:08:33+00:00 https://inventivapharma.com/fr/nouvelles-avancees-dans-le-developpement-clinique-de-lanifibranor-pour-le-traitement-de-la-nash-2-2-2-2/ 2019-04-15T06:27:24+00:00 https://inventivapharma.com/fr/inventiva-presentera-de-nouveaux-resultats-de-son-programme-yap-tead-en-oncologie/ 2019-04-23T15:46:21+00:00 https://inventivapharma.com/inventiva-to-present-new-results-of-its-yap-tead-oncology-program/ 2019-04-23T15:50:39+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-27-mai-2019-modalites-de-mise-a-disposition-des-documents-preparatoires/ 2019-05-09T16:00:25+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-27-mai-2019-modalites-de-mise-a-disposition-des-documents-preparatoires-2/ 2019-05-23T16:00:49+00:00 https://inventivapharma.com/inventiva-to-present-new-results-of-its-yap-tead-oncology-program-2/ 2019-05-23T16:03:26+00:00 https://inventivapharma.com/inventiva-to-present-at-the-jefferies-2019-healthcare-conference/ 2019-05-24T15:45:16+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-jefferies-2019-healthcare-conference/ 2019-05-24T15:45:23+00:00 https://inventivapharma.com/nawal-ouzren-and-heinz-maeusli-appointed-to-inventivas-board-of-directors/ 2019-05-29T06:00:07+00:00 https://inventivapharma.com/fr/nawal-ouzren-et-heinz-maeusli-nommes-au-conseil-dadministration-dinventiva/ 2019-05-29T06:00:57+00:00 https://inventivapharma.com/inventiva-announces-end-of-patient-recruitment-for-its-phase-iia-trial-in-the-treatment-of-mps-vi/ 2019-06-11T15:45:53+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-fin-du-recrutement-des-patients-pour-son-etude-de-phase-iia-dans-le-traitement-de-la-mps-vi/ 2019-06-11T15:45:59+00:00 https://inventivapharma.com/inventiva-announces-the-creation-of-its-scientific-advisory-board/ 2019-06-13T15:45:18+00:00 https://inventivapharma.com/fr/inventiva-enregistre-un-nouveau-brevet-aux-etats-unis-renforcant-la-protection-de-son-candidat-medicament-phare-lanifibranor/ 2019-06-13T15:45:19+00:00 https://inventivapharma.com/h1-20191-financial-information-and-corporate-business-update/ 2019-07-30T15:52:57+00:00 https://inventivapharma.com/inventiva-secures-new-patent-in-the-us-strengthening-the-protection-of-its-lead-product-candidate-lanifibranor/ 2019-08-20T16:50:20+00:00 https://inventivapharma.com/fr/de-nouveaux-resultats-prometteurs-de-lanifibranor-seront-presentes-lors-du-the-liver-meeting-2019/ 2019-08-27T12:01:11+00:00 https://inventivapharma.com/new-promising-results-on-lanifibranor-to-be-presented-at-the-liver-meeting-2019/ 2019-08-27T12:04:03+00:00 https://inventivapharma.com/inventiva-secures-a-new-european-patent-strengthening-and-extending-the-protection-of-its-lead-product-candidate-lanifibranor/ 2019-08-28T15:42:38+00:00 https://inventivapharma.com/fr/inventiva-enregistre-un-nouveau-brevet-europeen-renforcant-et-etendant-la-protection-de-son-candidat-medicament-phare-lanifibranor/ 2019-08-28T15:46:27+00:00 https://inventivapharma.com/odiparcil-development-advances-with-recruitment-of-first-patients-in-a-new-biomarker-study-in-mps-vi-children-and-adults/ 2019-09-02T15:05:01+00:00 https://inventivapharma.com/fr/le-developpement-dodiparcil-progresse-avec-le-recrutement-des-premiers-patients-dans-une-nouvelle-etude-biomarqueur-menee-chez-des-adultes-et-enfants-atteints-de-la-mps-vi/ 2019-09-02T15:29:37+00:00 https://inventivapharma.com/fr/inventiva-franchit-une-etape-cle-avec-la-fin-du-recrutement-des-patients-dans-son-etude-clinique-de-phase-iib-avec-lanifibranor-dans-la-nash/ 2019-09-04T15:42:39+00:00 https://inventivapharma.com/inventiva-achieves-a-major-milestone-by-completing-patient-recruitment-for-its-phase-iib-clinical-study-with-lanifibranor-in-nash/ 2019-09-04T15:44:36+00:00 https://inventivapharma.com/inventiva-announces-the-positive-recommendation-of-the-4-th-and-last-dsmb-of-the-phase-iib-clinical-study-with-lanifibranor-in-nash/ 2019-09-10T15:19:23+00:00 https://inventivapharma.com/fr/inventiva-annonce-l-avis-positif-du-4-eme-et-dernier-dsmb-de-letude-clinique-de-phase-iib-avec-lanifibranor-dans-la-nash/ 2019-09-10T15:21:10+00:00 https://inventivapharma.com/fr/inventiva-realise-une-augmentation-de-capital-de-82-millions-deuros-souscrite-par-des-investisseurs-americains-et-europeens-de-premier-plan-dans-le-secteur-des-biotechnologies/ 2019-09-19T05:59:14+00:00 https://inventivapharma.com/inventiva-completes-a-capital-increase-of-e-8-2-million-subscribed-by-leading-us-and-european-biotech-investors/ 2019-09-19T06:01:11+00:00 https://inventivapharma.com/h1-2019-financial-results-and-corporate-business-update/ 2019-09-25T15:44:13+00:00 https://inventivapharma.com/fr/resultats-financiers-du-1er-semestre-2019-et-point-sur-lactivite/ 2019-09-25T15:44:17+00:00 https://inventivapharma.com/inventiva-receives-fda-fast-track-designation-for-lead-asset-lanifibranor-in-nash/ 2019-09-26T15:59:55+00:00 https://inventivapharma.com/fr/inventiva-obtient-le-statut-fast-track-de-la-fda-pour-son-produit-candidat-phare-lanifibranor-dans-la-nash/ 2019-09-26T16:03:04+00:00 https://inventivapharma.com/fr/inventiva-realise-une-augmentation-de-capital-de-625-000-euros-souscrite-par-sofinnova-partners-au-travers-de-son-fonds-sofinnova-crossover-i-fund/ 2019-09-30T18:45:50+00:00 https://inventivapharma.com/inventiva-completes-a-capital-increase-of-e-625000-subscribed-by-sofinnova-partners-through-sofinnova-crossover-i-fund/ 2019-09-30T18:48:11+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-h-c-wainwright-3rd-annual-nash-investor-conference-et-au-gilbert-dupont-nash-day/ 2019-10-16T15:57:14+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-h-c-wainwright-3rd-annual-nash-investor-conference-and-the-gilbert-dupont-nash-day/ 2019-10-16T15:59:25+00:00 https://inventivapharma.com/inventiva-to-present-at-the-jefferies-2019-london-healthcare-conference/ 2019-11-12T16:44:21+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-jefferies-2019-london-healthcare-conference/ 2019-11-12T16:44:28+00:00 https://inventivapharma.com/q3-2019-financial-information-and-update-on-the-partnership-with-boehringer-ingelheim/ 2019-11-13T16:49:36+00:00 https://inventivapharma.com/fr/information-financiere-du-3eme-trimestre-2019-et-point-sur-le-partenariat-avec-boehringer-ingelheim/ 2019-11-13T17:15:42+00:00 https://inventivapharma.com/inventiva-receives-a-e3-5-m-milestone-payment-from-abbvie/ 2019-12-03T16:42:47+00:00 https://inventivapharma.com/fr/inventiva-recoit-un-paiement-detape-de-35-me-de-la-part-dabbvie/ 2019-12-03T16:42:54+00:00 https://inventivapharma.com/inventiva-announces-positive-results-from-phase-iia-clinical-study-with-odiparcil-in-mucopolysaccharidosis-type-vi/ 2019-12-18T17:27:41+00:00 https://inventivapharma.com/fr/inventiva-annonce-des-resultats-positifs-de-letude-clinique-de-phase-iia-avec-odiparcil-dans-la-mucopolysaccharidose-de-type-vi/ 2019-12-18T19:15:08+00:00 https://inventivapharma.com/fr/inventiva-eligible-au-srd-long-only-sur-le-marche-reglemente-deuronext-paris/ 2020-01-06T16:41:03+00:00 https://inventivapharma.com/inventiva-admitted-to-the-srd-long-only-on-the-regulated-market-of-euronext-paris/ 2020-01-06T16:43:15+00:00 https://inventivapharma.com/fr/inventiva-a-ete-retenue-pour-presenter-les-resultats-positifs-de-letude-clinique-de-phase-iia-avec-odiparcil-dans-la-mps-vi-lors-du-16eme-annual-worldsymposiumtm/ 2020-02-03T16:51:07+00:00 https://inventivapharma.com/inventiva-selected-to-present-the-positive-results-from-its-phase-iia-clinical-study-with-odiparcil-in-mps-vi-at-the-16th-annual-worldsymposiumtm/ 2020-02-03T17:16:09+00:00 https://inventivapharma.com/full-year-2019-cash-position-and-revenues/ 2020-02-05T16:49:11+00:00 https://inventivapharma.com/fr/exercice-2019-position-de-tresorerie-et-chiffre-daffaires/ 2020-02-05T16:53:02+00:00 https://inventivapharma.com/inventiva-completes-a-capital-increase-of-e15-m-subscribed-by-existing-shareholders/ 2020-02-07T07:47:03+00:00 https://inventivapharma.com/fr/inventiva-realise-une-augmentation-de-capital-de-15-me-souscrite-par-des-actionnaires-existants/ 2020-02-07T07:48:53+00:00 https://inventivapharma.com/fr/inventiva-met-a-disposition-un-prospectus-dans-le-cadre-de-ladmission-dactions-nouvelles-sur-euronext-paris/ 2020-02-10T08:46:05+00:00 https://inventivapharma.com/inventiva-to-present-at-the-cowen-and-company-40th-annual-health-care-conference/ 2020-02-19T16:38:50+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-cowen-and-company-40th-annual-health-care-conference/ 2020-02-19T16:40:55+00:00 https://inventivapharma.com/inventiva-files-a-prospectus-in-the-context-of-the-admission-to-trading-of-new-shares-on-euronext-paris/ 2020-02-25T16:28:45+00:00 https://inventivapharma.com/2019-full-year-results-significant-progress-in-nash-mps-vi-and-psoriasis-and-extended-cash-runway/ 2020-03-10T17:38:09+00:00 https://inventivapharma.com/inventiva-announces-completion-of-patient-visits-for-its-phase-iib-clinical-study-with-lanifibranor-in-nash/ 2020-03-17T16:40:49+00:00 https://inventivapharma.com/fr/inventiva-annonce-avoir-realise-la-derniere-visite-de-patient-pour-son-etude-clinique-de-phase-iib-avec-lanifibranor-dans-la-nash/ 2020-03-17T16:43:14+00:00 https://inventivapharma.com/fr/inventiva-fait-le-point-sur-ses-activites-dans-le-contexte-de-lepidemie-de-covid-19/ 2020-04-07T16:01:25+00:00 https://inventivapharma.com/fr/mise-a-disposition-du-rapport-financier-annuel-2019/ 2020-04-20T11:01:14+00:00 https://inventivapharma.com/inventiva-provides-a-corporate-business-update-in-the-context-of-the-covid-19-pandemic/ 2020-04-20T11:02:08+00:00 https://inventivapharma.com/fr/inventiva-fera-un-point-sur-letude-clinique-de-phase-iib-native-dans-la-nash-a-loccasion-dun-webcast-avec-des-leaders-dopinion/ 2020-04-21T15:27:11+00:00 https://inventivapharma.com/inventiva-to-provide-an-update-on-the-native-phase-iib-clinical-trial-in-nash-during-a-key-opinion-leader-webcast/ 2020-04-21T15:29:08+00:00 https://inventivapharma.com/shareholders-meeting-of-may-28-2020-availability-of-the-preparatory-documents-and-methods-for-participating-and-voting-at-the-meeting/ 2020-05-06T16:04:52+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-28-mai-2020-modalites-de-mise-a-disposition-des-documents-preparatoires-de-participation-et-de-vote/ 2020-05-06T16:07:13+00:00 https://inventivapharma.com/fr/information-financiere-du-1er-trimestre-2020/ 2020-05-14T16:47:29+00:00 https://inventivapharma.com/q1-2020-financial-information/ 2020-05-14T16:51:04+00:00 https://inventivapharma.com/fr/publication-des-dernieres-recherches-dinventiva-sur-le-mecanisme-daction-dodiparcil-dans-la-revue-scientifique-de-reference-plos-one/ 2020-05-18T16:27:16+00:00 https://inventivapharma.com/inventivas-latest-research-on-odiparcils-mechanism-of-action-published-in-leading-peer-reviewed-scientific-journal-plos-one/ 2020-05-18T16:29:46+00:00 https://inventivapharma.com/fr/inventiva-obtient-un-financement-non-dilutif-de-100-me-sous-forme-de-pret-garanti-par-letat-dans-le-contexte-de-la-pandemie-de-covid-19/ 2020-05-19T15:37:24+00:00 https://inventivapharma.com/inventiva-secures-e10-0-m-non-dilutive-loan-facility-guaranteed-by-the-french-state-in-the-context-of-the-covid-19-pandemic/ 2020-05-19T15:39:48+00:00 https://inventivapharma.com/inventiva-secures-a-new-patent-for-lanifibranor-in-china-expanding-the-protection-of-its-lead-product-candidate/ 2020-05-25T15:40:06+00:00 https://inventivapharma.com/fr/inventiva-enregistre-un-nouveau-brevet-pour-lanifibranor-en-chine-etendant-la-protection-de-son-candidat-medicament-phare/ 2020-05-25T15:42:06+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-jefferies-virtual-healthcare-conference/ 2020-06-02T16:33:18+00:00 https://inventivapharma.com/fr/inventiva-participera-a-la-jefferies-virtual-healthcare-conference/ 2020-06-02T16:34:45+00:00 https://inventivapharma.com/fr/inventiva-annonce-que-lanifibranor-a-atteint-le-critere-principal-et-les-criteres-secondaires-cles-de-letude-clinique-de-phase-iib-native-dans-la-steatohepatite-non-alcoolique-nash/ 2020-06-15T16:19:21+00:00 https://inventivapharma.com/inventiva-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/ 2020-06-19T21:31:46+00:00 https://inventivapharma.com/fr/inventiva-annonce-que-lanifibranor-a-atteint-le-critere-principal-et-les-criteres-secondaires-cles-de-letude-clinique-de-phase-iib-native-dans-la-steatohepatite-non-alcoolique-nash-2/ 2020-06-19T21:39:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-decision-de-linvestigateur-de-reduire-le-nombre-de-patients-dans-letude-de-phase-ii-en-cours-evaluant-lanifibranor-chez-des-patients-atteints-de-diabete-de-type-2-t2dm/ 2020-07-06T06:16:45+00:00 https://inventivapharma.com/fr/information-financiere-du-1er-semestre-2020/ 2020-07-06T16:27:51+00:00 https://inventivapharma.com/h1-2020-financial-information/ 2020-07-06T16:39:39+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-debut-du-roadshow-dans-le-cadre-de-son-projet-doffre-globale-et-de-son-projet-de-cotation-au-nasdaq/ 2020-07-06T16:47:19+00:00 https://inventivapharma.com/inventiva-announces-the-start-of-the-roadshow-for-its-proposed-global-offering-and-proposed-nasdaq-listing/ 2020-07-06T16:47:27+00:00 https://inventivapharma.com/inventiva-announces-the-decision-by-the-investigator-to-reduce-the-number-of-patients-in-the-ongoing-phase-ii-trial-evaluating-lanifibranor-in-type-2-diabetes-patients-t2dm-with-non-alcoholic-fatty/ 2020-07-08T14:56:22+00:00 https://inventivapharma.com/inventiva-announces-the-filing-of-an-amended-registration-statement-including-an-estimated-initial-public-offering-price-range/ 2020-07-08T21:58:33+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-depot-dun-amendement-au-document-denregistrement-form-f-1-incluant-une-fourchette-de-prix-indicative/ 2020-07-08T22:05:30+00:00 https://inventivapharma.com/inventiva-announces-the-pricing-of-its-initial-public-offering-on-the-nasdaq-global-market/ 2020-07-10T06:00:54+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-fixation-du-prix-de-son-introduction-en-bourse-sur-le-nasdaq-global-market/ 2020-07-10T06:01:02+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-suspension-temporaire-du-cours-de-ses-actions-ordinaires-sur-euronext-paris/ 2020-07-10T06:01:55+00:00 https://inventivapharma.com/inventiva-announces-temporary-trading-halt-of-its-ordinary-shares-on-euronext-paris/ 2020-07-10T12:30:58+00:00 https://inventivapharma.com/inventiva-announces-trading-resumption-of-its-ordinary-shares-on-euronext-paris/ 2020-07-10T12:35:09+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-reprise-des-negociations-de-ses-actions-ordinaires-sur-euronext-paris/ 2020-07-10T12:39:36+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-mise-a-disposition-dun-prospectus-dans-le-cadre-de-son-offre-au-public-dactions-ordinaires-sous-la-formes-dads-a-loccasion-de-son-introduction-en-bourse-sur-le-nasdaq-glob/ 2020-07-10T16:01:30+00:00 https://inventivapharma.com/inventiva-annonce-la-mise-a-disposition-dun-prospectus-dans-le-cadre-de-son-offre-au-public-dactions-ordinaires-sous-la-formes-dads-a-loccasion-de-son-introduction-en-bourse-sur-le-nasdaq-glob/ 2020-07-10T16:18:31+00:00 https://inventivapharma.com/inventiva-announces-the-closing-of-107-7-million-initial-public-offering-on-the-nasdaq-global-market/ 2020-07-15T18:40:48+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-realisation-de-son-introduction-en-bourse-sur-le-nasdaq-global-market-pour-un-montant-de-1077-millions-de-dollars-u-s/ 2020-07-16T15:00:45+00:00 https://inventivapharma.com/inventiva-to-participate-at-several-investor-conferences-in-september-2020/ 2020-09-09T16:31:33+00:00 https://inventivapharma.com/h1-2020-financial-results-corporate-business-update/ 2020-09-16T20:00:32+00:00 https://inventivapharma.com/fr/resultats-financiers-du-1er-semestre-2020-et-point-sur-lactivite/ 2020-09-16T20:00:15+00:00 https://inventivapharma.com/inventiva-to-participate-at-several-investor-conferences-in-october-2020/ 2020-09-24T16:15:43+00:00 https://inventivapharma.com/fr/inventiva-participera-a-plusieurs-conferences-investisseurs-en-septembre-2020/ 2020-09-24T16:09:32+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-octobre-2020/ 2020-09-24T16:15:30+00:00 https://inventivapharma.com/fr/inventiva-selectionnee-pour-presenter-les-resultats-de-son-etude-clinique-native-de-phase-iib-avec-lanifibranor-dans-la-nash-en-session-pleniere-lors-de-la-conference-the-liver-meeting-digital-experie/ 2020-10-05T20:00:11+00:00 https://inventivapharma.com/inventiva-selected-to-present-the-results-of-its-native-phase-iib-clinical-trial-with-lanifibranor-in-nash-during-a-plenary-session-at-the-liver-meeting-digital-experience-2020/ 2020-10-05T20:00:07+00:00 https://inventivapharma.com/inventiva-receives-fda-breakthrough-therapy-designation-for-lead-drug-candidate-lanifibranor-in-nash/ 2020-10-12T20:00:00+00:00 https://inventivapharma.com/fr/inventiva-recoit-le-statut-de-breakthrough-therapy-de-la-part-de-la-fda-pour-lanifibranor-son-principal-candidat-medicament-dans-la-nash/ 2020-10-12T20:00:25+00:00 https://inventivapharma.com/inventiva-receives-fda-fast-track-designation-in-mps-vi-for-its-clinical-stage-asset-odiparcil/ 2020-10-19T20:00:34+00:00 https://inventivapharma.com/inventiva-obtient-le-statut-fast-track-de-la-fda-pour-son-candidat-medicament-au-stade-clinique-odiparcil-dans-la-mps-vi/ 2020-10-19T20:00:03+00:00 https://inventivapharma.com/fr/inventiva-organisera-un-webcast-avec-des-leaders-dopinion-a-loccasion-du-the-liver-meeting-digital-experience-2020-de-laasld/ 2020-10-28T21:00:14+00:00 https://inventivapharma.com/inventiva-to-host-a-key-opinion-leader-webcast-from-the-aasld-the-liver-meeting-digital-experience-2020/ 2020-10-28T21:00:20+00:00 https://inventivapharma.com/inventiva-announces-the-additional-acceptance-of-two-late-breaking-abstracts-at-the-aasld-the-liver-meeting-digital-experience-2020/ 2020-11-02T07:00:59+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-selection-de-deux-nouveaux-abstracts-late-breaking-lors-du-the-liver-meeting-digital-experience-2020-organise-par-laasld/ 2020-11-02T07:03:22+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-publication-dun-article-scientifique-sur-le-role-des-ppar-dans-le-traitement-de-la-nash-dans-la-revue-medicale-nature-review-gastroenterology-hepatology/ 2020-11-02T21:01:02+00:00 https://inventivapharma.com/inventiva-announces-the-publication-of-a-scientific-paper-on-the-role-of-ppars-in-the-treatment-of-nash-in-the-medical-journal-nature-review-gastroenterology-hepatology/ 2020-11-02T21:01:08+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-nomination-du-dr-michael-cooreman-au-poste-de-directeur-medical/ 2020-11-05T21:00:01+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-stifel-virtual-healthcare-conference-2020-and-the-11th-jefferies-virtual-healthcare-conference/ 2020-11-09T21:00:05+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-stifel-virtual-healthcare-conference-2020-et-la-11th-jefferies-virtual-healthcare-conference/ 2020-11-09T21:00:56+00:00 https://inventivapharma.com/inventiva-receives-positive-fda-feedback-to-advance-its-lead-drug-candidate-lanifibranor-into-pivotal-phase-iii-in-nash/ 2020-11-12T09:24:24+00:00 https://inventivapharma.com/fr/inventiva-recoit-un-retour-positif-de-la-fda-pour-demarrer-le-developpement-en-phase-iii-de-lanifibranor-son-principal-candidat-medicament-dans-la-nash/ 2020-11-12T09:24:47+00:00 https://inventivapharma.com/q3-2020-financial-information/ 2020-11-12T21:00:31+00:00 https://inventivapharma.com/fr/information-financiere-du-3eme-trimestre-2020/ 2020-11-12T21:04:41+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference/ 2020-11-24T21:00:12+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-piper-sandler-32nd-annual-virtual-healthcare-conference/ 2020-11-24T21:00:12+00:00 https://inventivapharma.com/inventiva-announces-the-publication-in-the-journal-of-hepatology-of-new-pre-clinical-data-showing-the-beneficial-effects-of-lanifibranor-on-cirrhosis/ 2020-12-07T21:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-publication-dans-la-revue-journal-of-hepatology-de-nouvelles-donnees-pre-cliniques-demontrant-les-effets-benefiques-de-lanifibranor-sur-la-cirrhose/ 2020-12-07T21:00:27+00:00 https://inventivapharma.com/inventiva-announces-design-of-phase-iii-clinical-trial-with-lanifibranor-in-nash/ 2021-01-05T21:01:18+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-design-de-son-etude-clinique-de-phase-iii-avec-lanifibranor-dans-la-nash/ 2021-01-06T08:07:07+00:00 https://inventivapharma.com/inventiva-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference/ 2021-01-06T21:00:07+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-39th-annual-j-p-morgan-healthcare-conference/ 2021-01-06T21:00:44+00:00 https://inventivapharma.com/full-year-2020-cash-position-and-revenues/ 2021-02-11T21:00:34+00:00 https://inventivapharma.com/fr/exercice-2020-position-de-tresorerie-et-chiffre-daffaires/ 2021-02-11T21:00:00+00:00 https://inventivapharma.com/fr/presentation-des-resultats-financiers-2020-dinventiva/ 2021-02-23T21:01:49+00:00 https://inventivapharma.com/inventivas-2020-full-year-financial-results-presentation/ 2021-02-23T21:01:58+00:00 https://inventivapharma.com/fr/inventiva-participera-a-plusieurs-conferences-investisseurs-en-mars-2021/ 2021-02-24T21:00:13+00:00 https://inventivapharma.com/inventiva-to-participate-at-several-investor-conferences-in-march-2021/ 2021-02-24T21:01:13+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-16-avril-2021-modalites-de-mise-a-disposition-des-documents-preparatoires-de-participation-et-de-vote/ 2021-03-25T17:00:39+00:00 https://inventivapharma.com/appointment-of-martine-zimmermann-as-independent-director-to-inventivas-board-of-directors/ 2021-04-19T21:11:43+00:00 https://inventivapharma.com/fr/nomination-de-martine-zimmermann-en-tant-quadministratrice-independante-au-conseil-dadministration-dinventiva/ 2021-04-19T21:12:58+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-7th-annual-truist-securities-life-sciences-summit/ 2021-04-26T20:00:07+00:00 https://inventivapharma.com/inventiva-reports-first-quarter-2021-financial-information-and-updates-on-the-collaboration-with-abbvie-in-auto-immune-diseases/ 2021-06-10T07:27:08+00:00 https://inventivapharma.com/inventiva-announces-the-appointment-of-dr-michael-cooreman-as-chief-medical-officer/ 2021-06-10T08:32:14+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-jefferies-virtual-healthcare-conference-2/ 2021-06-15T15:22:46+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-au-svb-leerink-cyberx-series-liver-disease-day/ 2021-06-15T20:00:38+00:00 https://inventivapharma.com/svb-leerink-cyberx-series-liver-disease-day/ 2021-06-15T20:00:23+00:00 https://inventivapharma.com/fr/inventiva-annonce-trois-presentations-scientifiques-lors-du-easl-international-liver-congress-2021-et-dun-webcast-avec-des-leaders-dopinion/ 2021-06-15T15:31:22+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-jefferies-virtual-healthcare-conference/ 2021-06-15T15:32:54+00:00 https://inventivapharma.com/fr/inventiva-information-financiere-du-1er-trimestre-2021-et-point-sur-le-partenariat-avec-abbvie-dans-le-domaine-des-maladies-auto-immunes/ 2021-06-15T15:33:01+00:00 https://inventivapharma.com/inventiva-to-participate-at-the-7th-annual-truist-securities-life-sciences-summit/ 2021-06-15T15:37:08+00:00 https://inventivapharma.com/shareholders-meeting-of-april-16-2021-availability-of-the-preparatory-documents-and-methods-for-participating-and-voting/ 2021-06-16T14:18:59+00:00 https://inventivapharma.com/inventiva-announces-filing-of-its-2020-universal-registration-document-and-2020-annual-report-on-form-20-f/ 2021-06-16T14:24:03+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-depot-de-son-document-denregistrement-universel-2020-et-de-son-rapport-annuel-2020-form-20-f/ 2021-06-16T14:24:18+00:00 https://inventivapharma.com/fr/resultats-annuels-2020-avancees-majeures-dans-la-nash-et-visibilite-financiere-significativement-etendue-suite-au-succes-de-lintroduction-en-bourse-aux-etats-unis/ 2021-06-16T14:25:04+00:00 https://inventivapharma.com/2020-full-year-results-major-advances-in-nash-and-significantly-extended-cash-runway-through-successful-ipo-in-the-united-states/ 2021-06-16T14:25:33+00:00 https://inventivapharma.com/fr/inventiva-annonce-une-collaboration-pour-developper-des-biomarqueurs-non-invasifs-permettant-lidentification-de-patients-chez-lesquels-lanifibranor-conduit-a-une-resolution-de-la-nash-et-a-un/ 2021-06-16T14:26:01+00:00 https://inventivapharma.com/inventiva-announces-collaboration-on-non-invasive-biomarkers-to-identify-patients-responding-to-lanifibranor-with-regards-to-nash-resolution-and-fibrosis-improvement/ 2021-06-16T14:26:20+00:00 https://inventivapharma.com/fr/inventiva-presente-ses-informations-financieres-du-1er-semestre-2021/ 2021-07-28T20:32:51+00:00 https://inventivapharma.com/inventiva-reports-first-half-of-2021-financial-information/ 2021-07-28T20:33:14+00:00 https://inventivapharma.com/inventiva-announces-the-implementation-of-an-at-the-market-program-in-the-united-states/ 2021-08-02T21:01:02+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-mise-en-place-dun-programme-de-financement-en-fonds-propres-aux-etats-unis/ 2021-08-02T21:33:31+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-investor-conferences-in-september-2021/ 2021-08-30T20:00:30+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-septembre-2021/ 2021-08-30T20:00:30+00:00 https://inventivapharma.com/inventivas-2021-first-half-financial-results-presentation/ 2021-09-10T13:00:35+00:00 https://inventivapharma.com/fr/inventiva-annonce-des-recrutements-cles-pour-accelerer-le-developpement-de-lanifibranor-dans-la-nash/ 2021-09-16T20:00:59+00:00 https://inventivapharma.com/inventiva-announces-major-recruitments-to-accelerate-the-development-of-lanifibranor-in-nash/ 2021-09-16T20:00:02+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-resultats-financiers-du-1er-semestre-2021-et-fait-un-point-sur-ses-activites/ 2021-09-20T20:00:06+00:00 https://inventivapharma.com/inventiva-completes-sale-of-30-million/ 2021-09-23T06:16:55+00:00 https://inventivapharma.com/fr/inventiva-leve-30-millions-de-dollars/ 2021-09-23T06:17:36+00:00 https://inventivapharma.com/inventiva-reports-2021-first-half-financial-results-and-provides-a-corporate-update/ 2021-09-24T22:42:23+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-octobre-2021/ 2021-09-28T20:00:41+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-investor-conferences-in-october-2021/ 2021-09-28T20:00:55+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-de-cinq-abstracts-scientifiques-lors-du-the-liver-meeting-2021-organise-par-laasld/ 2021-10-18T20:00:32+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-investor-conferences-in-november-2021/ 2021-10-29T13:30:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-novembre-2021/ 2021-10-29T13:31:39+00:00 https://inventivapharma.com/fr/inventiva-organise-un-webcast-avec-des-leaders-dopinion-a-loccasion-du-congres-the-liver-meeting-2021-de-laasld/ 2021-11-03T20:00:51+00:00 https://inventivapharma.com/inventiva-to-host-a-webcast-with-key-opinion-leaders-from-the-aasld-the-liver-meeting-2021/ 2021-11-03T20:00:16+00:00 https://inventivapharma.com/inventiva-reports-2021-third-quarter-financial-information/ 2021-11-10T21:00:30+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-informations-financieres-du-3eme-trimestre-2021/ 2021-11-10T21:00:11+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-la-40th-annual-j-p-morgan-healthcare-conference/ 2021-12-16T21:00:10+00:00 https://inventivapharma.com/inventiva-to-present-at-the-40th-annual-j-p-morgan-healthcare-conference/ 2021-12-16T21:19:32+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-janvier-et-fevrier-2022/ 2022-01-20T21:00:52+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-conferences-in-january-and-february-2022/ 2022-01-20T21:00:27+00:00 https://inventivapharma.com/inventiva-announces-positive-results-of-clinical-thorough-qt-study-conducted-with-lanifibranor/ 2022-01-25T11:24:01+00:00 https://inventivapharma.com/inventiva-announces-the-design-of-legend-a-phase-iia-combination-trial-with-lanifibranor-and-sglt2-inhibitor-empagliflozin-in-patients-with-nash-and-type-2-diabetes/ 2022-01-25T11:24:30+00:00 https://inventivapharma.com/the-new-england-journal-of-medicine-publishes-the-results-of-the-native-phase-iib-clinical-trial-with-lanifibranor-in-nash/ 2022-01-25T11:24:59+00:00 https://inventivapharma.com/presentation-aasld/ 2022-01-25T11:26:01+00:00 https://inventivapharma.com/inventiva-announces-fda-decision-that-fast-track-designation-granted-to-lanifibranor-in-nash-encompasses-the-treatment-of-nash-with-compensated-cirrhosis/ 2022-01-25T11:26:28+00:00 https://inventivapharma.com/inventiva-announces-the-initiation-of-its-pivotal-phase-iii-clinical-trial-evaluating-lanifibranor-in-nash/ 2022-01-25T11:26:50+00:00 https://inventivapharma.com/inventiva-announces-three-scientific-presentations-at-the-easl-international-liver-congress-2021-and-during-a-kol-webcast-event/ 2022-01-25T11:27:12+00:00 https://inventivapharma.com/fr/inventiva-recoit-un-paiement-detape-de-4-me-de-la-part-dabbvie-suite-au-lancement-de-letude-de-phase-iib-avec-cedirogant/ 2022-01-31T21:00:49+00:00 https://inventivapharma.com/inventiva-receives-a-e4-million-milestone-payment-from-abbvie-for-cedirogant-phase-iib-initiation/ 2022-01-31T21:00:26+00:00 https://inventivapharma.com/inventiva-reports-cash-position-and-revenues-for-full-year-2021/ 2022-02-14T21:02:53+00:00 https://inventivapharma.com/fr/inventiva-publie-sa-position-de-tresorerie-et-son-chiffre-daffaires-pour-lexercice-2021/ 2022-02-14T21:02:58+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-date-de-publication-et-de-presentation-de-ses-resultats-financiers-2021/ 2022-02-28T21:03:52+00:00 https://inventivapharma.com/inventiva-announces-the-schedule-of-publication-and-presentation-of-its-2021-full-year-financial-results/ 2022-02-28T21:03:58+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-conferences-in-march-2022/ 2022-03-01T21:02:45+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-mars-2022/ 2022-03-01T21:02:53+00:00 https://inventivapharma.com/inventiva-reports-its-2021-full-year-results-key-milestones-achieved-with-lanifibranor-in-nash-and-cedirogant-in-psoriasis/ 2022-03-07T21:02:24+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-resultats-annuels-2021-avancees-majeures-avec-lanifibranor-dans-la-nash-et-cedirogant-dans-le-psoriasis/ 2022-03-07T21:04:27+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-depot-de-son-document-denregistrement-universel-2021-et-de-son-rapport-annuel-2021-form-20-f/ 2022-03-11T21:01:41+00:00 https://inventivapharma.com/inventiva-announces-filing-of-its-2021-universal-registration-document-and-2021-annual-report-on-form-20-f/ 2022-03-11T21:01:46+00:00 https://inventivapharma.com/inventiva-announces-the-presentation-of-a-scientific-abstract-at-the-next-international-conference-on-fatty-liver/ 2022-04-07T20:06:22+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-dun-abstract-scientifique-lors-de-la-prochaine-international-conference-on-fatty-liver/ 2022-04-07T20:06:26+00:00 https://inventivapharma.com/combined-general-meeting-of-may-19-2022-availability-of-the-preparatory-documents/ 2022-04-28T13:59:05+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-19-mai-2022-modalites-de-mise-a-disposition-des-documents-preparatoires/ 2022-04-28T13:59:21+00:00 https://inventivapharma.com/statement-of-total-voting-rights-and-shares-forming-the-companys-share-capital-as-of-april-11-2022/ 2022-04-28T13:59:50+00:00 https://inventivapharma.com/fr/information-relative-au-nombre-total-de-droits-de-vote-et-dactions-composant-le-capital-social-au-11-avril-2022/ 2022-04-28T14:00:08+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-decision-de-la-fda-que-le-statut-fast-track-accorde-a-lanifibranor-dans-la-nash-englobe-le-traitement-de-la-nash-avec-cirrhose-compensee/ 2022-05-09T08:51:19+00:00 https://inventivapharma.com/inventiva-announces-that-its-ind-application-for-the-phase-ii-combination-trial-with-lanifibranor-and-empagliflozin-in-patients-with-nash-and-t2d-has-been-accepted-by-the-fda/ 2022-05-09T08:54:13+00:00 https://inventivapharma.com/fr/inventiva-annonce-que-la-fda-accepte-sa-demande-d-investigational-new-drug-pour-lessai-clinique-de-phase-ii-combinant-lanifibranor-et-empagliflozine-chez-des-patients-at/ 2022-05-09T08:54:23+00:00 https://inventivapharma.com/fr/inventiva-annonce-les-resultats-positifs-de-letude-clinique-thorough-qt-menee-avec-lanifibranor/ 2022-05-09T08:55:45+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-design-de-legend-un-essai-clinique-de-phase-iia-combinant-lanifibranor-et-empagliflozine-un-inhibiteur-du-sglt2-chez-des-patients-atteints-de-la-nash-et-de-diabete-de-type-2/ 2022-05-09T08:55:52+00:00 https://inventivapharma.com/fr/the-new-england-journal-of-medicine-publie-les-resultats-de-letude-clinique-de-phase-iib-native-dinventiva-avec-lanifibranor-dans-la-nash/ 2022-05-09T08:56:02+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-lancement-de-letude-clinique-pivot-de-phase-iii-evaluant-lanifibranor-dans-la-nash/ 2022-05-09T08:57:03+00:00 https://inventivapharma.com/inventiva-secures-a-e50-million-credit-facility-from-the-european-investment-bank/ 2022-05-16T06:00:09+00:00 https://inventivapharma.com/fr/inventiva-obtient-un-credit-dun-montant-de-50-millions-deuros-de-la-part-de-la-banque-europeenne-dinvestissement/ 2022-05-16T06:02:45+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-informations-financieres-du-1er-trimestre-2022-et-fait-un-point-sur-ses-developpements-cliniques/ 2022-05-16T20:02:28+00:00 https://inventivapharma.com/inventiva-reports-2022-first-quarter-financial-information-and-provides-clinical-development-update/ 2022-05-16T20:07:19+00:00 https://inventivapharma.com/fr/descriptif-du-programme-de-rachat-daction-autorise-par-lassemblee-generale-ordinaire-du-19-mai-2022/ 2022-05-19T20:00:34+00:00 https://inventivapharma.com/description-of-the-share-repurchase-program-authorised-by-the-ordinary-general-meeting-of-19-may-2022/ 2022-05-19T20:00:52+00:00 https://inventivapharma.com/fr/resultats-des-votes-de-lassemblee-generale-mixte-des-actionnaires-reunie-le-19-mai-2022/ 2022-05-20T20:00:53+00:00 https://inventivapharma.com/results-of-the-votes-of-the-combined-shareholders-meeting-of-may-19-2022/ 2022-05-20T20:00:58+00:00 https://inventivapharma.com/inventiva-announces-participation-at-several-investors-conferences-in-may-and-june-2022/ 2022-05-23T20:04:53+00:00 https://inventivapharma.com/fr/inventiva-annonce-sa-participation-a-plusieurs-conferences-investisseurs-en-mai-et-juin-2022/ 2022-05-23T20:05:09+00:00 https://inventivapharma.com/inventiva-announces-the-presentation-of-a-scientific-abstract-at-the-82nd-scientific-sessions-of-the-american-diabetes-association/ 2022-06-03T20:00:15+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-dun-abstract-scientifique-lors-de-la-82nd-scientific-sessions-of-the-american-diabetes-association/ 2022-06-03T20:01:16+00:00 https://inventivapharma.com/inventiva-joins-the-euronext-tech-leaders-segment/ 2022-06-07T20:00:58+00:00 https://inventivapharma.com/fr/inventiva-integre-le-segment-tech-leaders-deuronext/ 2022-06-07T20:01:04+00:00 https://inventivapharma.com/inventiva-announces-three-scientific-presentations-at-the-easl-international-liver-congress-2022/ 2022-06-09T20:01:01+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-de-trois-abstracts-scientifiques-lors-de-leasl-international-liver-congress-2022/ 2022-06-09T20:01:11+00:00 https://inventivapharma.com/fr/inventiva-organise-un-webcast-avec-des-leaders-dopinion-a-loccasion-de-leasl-international-liver-congress-2022/ 2022-06-16T20:12:02+00:00 https://inventivapharma.com/inventiva-to-host-a-webcast-with-key-opinion-leaders-following-the-easl-international-liver-congress-2022/ 2022-06-16T20:12:06+00:00 https://inventivapharma.com/fr/point-sur-la-situation-de-tresorerie-dinventiva-et-sur-le-credit-conclu-avec-la-banque-europeenne-dinvestissement/ 2022-07-04T16:48:32+00:00 https://inventivapharma.com/update-on-inventivas-cash-position-and-on-the-finance-documentation-with-the-european-investment-bank/ 2022-07-04T16:48:46+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-screening-du-premier-patient-dans-lessai-clinique-de-phase-iia-legend-combinant-lanifibranor-et-empagliflozine-chez-des-patients-atteints-de-la-nash-et-de-dt2/ 2022-07-07T20:22:02+00:00 https://inventivapharma.com/inventiva-announces-the-screening-of-the-first-patient-in-legend-a-phase-iia-combination-trial-with-lanifibranor-and-empagliflozin-in-patients-with-nash-and-t2d/ 2022-07-07T20:22:19+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-informations-financieres-du-1er-semestre-2022/ 2022-07-28T20:01:14+00:00 https://inventivapharma.com/inventiva-reports-2022-first-half-financial-information/ 2022-07-28T20:01:19+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-date-de-publication-et-de-presentation-de-ses-resultats-du-1er-semestre-2022/ 2022-09-07T20:01:26+00:00 https://inventivapharma.com/inventiva-announces-the-schedule-of-publication-and-presentation-of-its-2022-half-year-financial-results/ 2022-09-07T20:01:39+00:00 https://inventivapharma.com/fr/inventiva-et-sino-biopharm-signent-un-accord-de-licence-et-de-collaboration-pour-developper-et-commercialiser-lanifibranor-en-chine/ 2022-09-21T20:40:13+00:00 https://inventivapharma.com/inventiva-and-sino-biopharm-announce-licensing-and-collaboration-agreement-to-develop-and-commercialize-lanifibranor-in-greater-china/ 2022-09-21T20:41:04+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-resultats-financiers-du-1er-semestre-2022-et-fait-un-point-sur-ses-activites/ 2022-09-22T06:44:32+00:00 https://inventivapharma.com/inventiva-reports-its-2022-first-half-financial-results-and-provides-a-corporate-update/ 2022-09-23T12:12:46+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-presentation-dun-abstract-scientifique-lors-du-the-liver-meeting-2022-organise-par-laasld/ 2022-10-21T20:00:44+00:00 https://inventivapharma.com/inventiva-announces-a-scientific-presentation-at-the-aasld-the-liver-meeting-2022/ 2022-10-21T20:00:46+00:00 https://inventivapharma.com/inventiva-provides-update-dev-cedirogant-by-abbvie/ 2022-10-31T07:00:48+00:00 https://inventivapharma.com/fr/inventiva-fait-point-dev-cedirogant-par-abbvie/ 2022-10-31T07:00:35+00:00 https://inventivapharma.com/inventiva-reports-2022-third-quarter-financial-information/ 2022-11-21T19:53:12+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-informations-financieres-du-3eme-trimestre-2022/ 2022-11-21T19:53:40+00:00 https://inventivapharma.com/inventiva-announces-a-new-director-of-the-board-of-directors/ 2022-11-21T21:00:00+00:00 https://inventivapharma.com/fr/inventiva-annonce-larrivee-dun-nouveau-directeur-au-sein-de-son-conseil-dadministration/ 2022-11-21T21:01:01+00:00 https://inventivapharma.com/fr/inventiva-obtient-un-nouveau-brevet-elargissant-la-protection-de-la-propriete-intellectuelle-de-son-produit-candidat-phare-lanifibranor-aux-etats-unis/ 2022-11-28T21:00:04+00:00 https://inventivapharma.com/inventiva-secures-a-new-patent-expanding-the-ip-protection-of-its-lead-product-candidate-lanifibranor-in-the-us/ 2022-11-28T21:00:47+00:00 https://inventivapharma.com/inventiva-draws-down-e25-million-tranche-under-finance-contract-with-the-european-investment-bank/ 2022-12-12T07:30:53+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-tirage-de-la-premiere-tranche-de-25-millions-deuros-dans-le-cadre-de-son-contrat-de-financement-avec-la-banque-europeenne-dinvestissement/ 2022-12-12T07:30:58+00:00 https://inventivapharma.com/combined-general-meeting-of-january-25-2023-availability-of-the-preparatory-documents/ 2023-01-03T07:30:58+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-25-janvier-2023-modalites-de-mise-a-disposition-des-documents-preparatoires/ 2023-01-03T07:31:08+00:00 https://inventivapharma.com/fr/information-relative-au-nombre-total-de-droits-de-vote-et-dactions-composant-le-capital-social-au-19-decembre-2022/ 2023-01-03T07:35:16+00:00 https://inventivapharma.com/statement-of-total-voting-rights-and-shares-forming-the-companys-share-capital-as-of-december-19-2022/ 2023-01-03T07:35:31+00:00 https://inventivapharma.com/fr/inventiva-annonce-des-changements-au-developpement-clinique-de-lanifibranor-notamment-la-preparation-dune-nouvelle-etude-de-phase-iii-chez-les-patients-atteints-de-nash-avec-une-cirrhose-comp/ 2023-01-04T21:00:52+00:00 https://inventivapharma.com/inventiva-announces-changes-to-the-clinical-development-of-lanifibranor-including-plans-for-a-new-phase-iii-trial-in-patients-with-nash-and-compensated-cirrhosis/ 2023-01-04T21:01:00+00:00 https://inventivapharma.com/results-of-the-votes-of-the-combined-shareholders-general-meeting-of-january-25-2023/ 2023-01-26T07:00:38+00:00 https://inventivapharma.com/fr/resultats-des-votes-de-lassemblee-generale-mixte-des-actionnaires-reunie-le-25-janvier-2023/ 2023-01-26T07:00:37+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-resultats-financiers-preliminaires-pour-lexercice-2022/ 2023-02-14T21:02:10+00:00 https://inventivapharma.com/inventiva-reports-preliminary-financial-results-for-full-year-2022/ 2023-02-14T21:02:19+00:00 https://inventivapharma.com/inventiva-announces-the-schedule-of-publication-and-presentation-of-its-2022-full-year-financial-results/ 2023-03-23T20:02:04+00:00 https://inventivapharma.com/fr/inventiva-annonce-la-date-de-publication-et-de-presentation-de-ses-resultats-financiers-2022/ 2023-03-23T20:02:10+00:00 https://inventivapharma.com/inventiva-reports-its-2022-full-year-results/ 2023-03-29T20:00:57+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-resultats-annuels-2022/ 2023-03-29T20:00:12+00:00 https://inventivapharma.com/fr/inventiva-annonce-le-depot-de-son-document-denregistrement-universel-2022-et-de-son-rapport-annuel-2022-form-20-f/ 2023-03-30T09:08:55+00:00 https://inventivapharma.com/inventiva-announces-filing-of-its-2022-universal-registration-document-and-2022-annual-report-on-form-20-f/ 2023-03-30T09:09:05+00:00 https://inventivapharma.com/combined-general-meeting-of-may-25-2023-availability-of-the-preparatory-documents/ 2023-05-04T06:30:37+00:00 https://inventivapharma.com/fr/assemblee-generale-mixte-du-25-mai-2023-modalites-de-mise-a-disposition-des-documents-preparatoires/ 2023-05-04T06:30:33+00:00 https://inventivapharma.com/fr/information-relative-au-nombre-total-de-droits-de-vote-et-dactions-composant-le-capital-social-au-17-avril-202/ 2023-05-04T06:35:57+00:00 https://inventivapharma.com/statement-of-total-voting-rights-and-shares-forming-the-companys-share-capital-as-of-april-17-2023/ 2023-05-04T06:36:01+00:00 https://inventivapharma.com/inventiva-reports-2023-first-quarter-financial-information-and-provides-a-corporate-update/ 2023-05-16T20:00:25+00:00 https://inventivapharma.com/fr/inventiva-publie-ses-informations-financieres-du-1er-trimestre-20231-et-fait-un-point-sur-ses-activites/ 2023-05-16T20:01:08+00:00 https://inventivapharma.com/inventivas-lanifibranor-meets-the-primary-and-key-secondary-endpoints-in-the-phase-iib-native-clinical-trial-in-non-alcoholic-steatohepatitis-nash/ 2023-09-26T00:33:51+00:00